Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors

Proteomics

Volumn 9, Issue 24, 2009, Pages 5437-5445

  Naldi, Marina ^a   Calonghi, Natalia ^a   Masotti, Lanfranco ^a   Parolin, Carola ^a   Valente, Sergio ^b   Mai, Antonello ^b   Andrisano, Vincenza ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Animal proteomics ; Histones acetylation ; LC ESI MS ; MS 275 ; SAHA ; Selective hdac inhibitors

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; MC 1568; MC 1855; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ARTICLE; CELL CYCLE ARREST; CELL STRAIN HT29; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS;

ADENOCARCINOMA; CELL CYCLE; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HT29 CELLS; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

ANIMALIA;

EID: 73149088831     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800866     Document Type: Article

References (27)

1. Smith, L. T., Otterson, G. A., Plass, C., Unraveling the epigenetic code of cancer for therapy. Trends Genet. 2007, 23, 449-456.
2. Bruserud, Ø., Stapnes, C., Ersvaer, E., Gjertsen, B.T., Ryningen, A., Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 2007, 8, 388-400.
3. Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S. et al., Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005, 25, 261-309.
4. Bhaumik, S. R., Smith, E., Shilatifard, A., Covalent modifications of histones during development and disease pathogenesis. Nat. Rev. 2007, 14, 1008-1016.
5. Margueron, R., Trojer, P., Reinberg, D., The key to development: interpreting the histone code. Curr. Opin. Genet. Dev. 2005, 15, 163-176.
6. Nightingale, K. P., O'Neill, L. P., Turner, B. M., Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 2006, 16, 125-136.
7. Turner, B. M., Histone acetylation and an epigenetic code. Bioessays 2000, 22, 836-845.
8. Kouzarides, T., Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9, 40-48.
9. Bolden, J. E., Peart, M. J., Johnstone, R. W., Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug. Discovery 2006, 5, 769-784.
10. Minucci, S., Pelicci, P. G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51.
11. Johnstone, R. W., Histone-deacetylase inibitors: novel drugs for the treatment of cancer. Nat. Rev. 2002, 1, 287-299.
12. De Ruijter, A. J. M., Van Gennip, A. H., Caron, H. N., Kemp, S., Van Kuilenburg, A. B. P., Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
13. Khabele, D., Son, D. S., Parl, A. K., Goldberg, G. L. et al., Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol. Ther. 2007, 6, 795-801.
14. Hess-Stumpp, H., Bracker, T. U., Henderson, D., Politz, O., MS-275, a potent orally vailable inhibitor of histone deacetylases - The development of an anticancer agent. Int. J. Biochem. Cell Biol. 2007, 39, 1388-1405.
15. Savarino, A., Mai, A., Norelli, S., El Daker, S. et al., "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiscence. Retrovirology, 2009, 6, 52-61.
16. Mai, A., Massa, S., Pezzi, R., Rotili, D. et al., Discovery of (aryloxopropenyl)pyrrolyl hydroxamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 2003, 46, 4826-4829.
17. Mai, A., Massa, S., Pezzi, R., Simeoni, S. et al., Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. J. Med. Chem. 2005, 48, 3344-3353.
18. Inoue, S., Mai, A., Dyer, M. J. S., Cohen, G. M., Inhibition of histone deacetylase class i but not class ii is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-induced apoptosis. Cancer Res. 2006, 66, 6785-6792.
19. Illi, B., Dello Russo, C., Colussi, C., Rosati, J. et al., Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ. Res. 2008, 102, 51-58.
20. Scognamiglio, A., Nebbioso, A., Manzo, F., Valente, S. et al., HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim. Biophys. Acta 2008, 1783, 2030-2038.
21. Marks, P., Breslow, R., Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25, 84-90.
22. Su, X., Ren, C., Freitas, M. A., Mass spectrometry-based strategies for characterization of histones and their post-translational modifications. Expert Rev. Proteomics 2007, 4, 211-225.
23. Naldi, M., Andrisano, V., Fiori, J., Calonghi, N. et al., Histone proteins determined in a human colon cancer by high-performance liquid chromatography and mass spectrometry. J. Chromatogr. A 2006, 1129, 73-81.
24. Olmo, S., Gotti, R., Naldi, M., Andrisano, V. et al., Analysis of human histone H4 by capillary electrophoresis in a pullulan-coated capillary, LC-ESI-MS and MALDI-TOF-MS. Anal. Bioanal. Chem. 2008, 390, 1881-1888.
25. Amellem, O., Stokke, T., Sandvik, J. A., Pettersen, E. O., The retinoblastoma gene product is reversibly dephosphorylated and bound in the nucleus in S and G2 phases during hypoxic stress. Exp. Cell Res. 1996, 227, 106.
26. Calonghi, N., Cappadone, C., Pagnotta, E., Boga, C. et al., Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. J. Lipid Res. 2005, 46, 1596.
27. Beckers, T, Burkhardt, C., Wieland, H., Gimmnich, P. et al., Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer 2007, 121, 1138-1148.